Last quarter (Q4 2023), Mineralys Therapeutics, Inc.'s total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Mineralys Therapeutics, Inc.'s net income was $-54.27M. See Mineralys Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20
Total Revenue	-	-	$ 0.00	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-
Gross Profit	-	-	-	-	-
Operating Expense	$ 84.66M	$ 84.66M	$ 31.48M	$ 18.73M	$ 2.94M
Operating Income	$ -84.66M	$ -84.66M	$ -31.48M	$ -18.73M	$ -2.94M
Net Non Operating Interest Income Expense	$ 12.76M	$ 12.76M	$ 1.68M	$ -27.00K	$ -115.00K
Other Income Expense	$ -3.00K	$ -3.00K	$ 4.00K	$ -656.00K	$ -368.00K
Pretax Income	$ -71.90M	$ -71.90M	$ -29.80M	$ -19.41M	$ -3.43M
Tax Provision	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-
Net Income Common Stockholders	$ -71.90M	$ -71.90M	$ -29.80M	$ -18.72M	$ -3.43M
Basic EPS	$ -2.00	$ -1.99	$ -0.76	$ -1.89	$ -0.35
Diluted EPS	$ -2.00	$ -1.99	$ -0.76	$ -1.89	$ -0.35
Basic Average Shares	$ 144.75M	$ 36.19M	$ 39.06M	$ 9.91M	$ 9.91M
Diluted Average Shares	$ 144.75M	$ 36.19M	$ 39.06M	$ 9.91M	$ 9.91M
Dividend Per Share	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-
Total Expenses	$ 84.66M	$ 84.66M	$ 31.48M	$ 18.73M	$ 2.94M
Net Income From Continuing And Discontinued Operation	$ -71.90M	$ -71.90M	$ -29.80M	$ -19.41M	$ -3.43M
Normalized Income	$ -70.44M	$ -56.80M	$ -29.80M	$ -19.41M	$ -3.43M
Interest Expense	-	-	-	$ 27.00K	$ 115.00K
EBIT	$ -71.90M	$ -71.90M	$ -31.48M	$ -19.38M	$ -3.31M
EBITDA	$ -54.04M	$ -78.76M	$ -31.48M	$ -19.38M	$ -3.31M

Currency in USD

Mineralys Therapeutics, Inc. Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing